Detalhe da pesquisa
1.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol
; 187(3): 338-352, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484697
2.
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.
Exp Dermatol
; 30(11): 1650-1661, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003519
3.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
; 83(3): 839-846, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344071
4.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10143): 222-231, 2018 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043749
5.
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Nephrol Dial Transplant
; 33(11): 1950-1959, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481660
6.
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
J Clin Endocrinol Metab
; 108(12): 3122-3134, 2023 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390454
7.
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
Crit Care
; 14(6): R229, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21176144
8.
Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry.
Crit Care
; 14(3): R102, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525247
9.
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
JAMA Dermatol
; 156(12): 1333-1343, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001140
10.
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
Crit Care
; 13(3): R103, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19566927
11.
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
J Clin Invest
; 128(7): 3041-3052, 2018 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649002
12.
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
Crit Care
; 9(4): R331-43, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16137345
13.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Intensive Care Med
; 29(6): 894-903, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12712239
14.
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.
Crit Care
; 10(5): 424, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17094791
15.
Drotrecogin alfa (activated) in severe sepsis.
Lancet Infect Dis
; 13(2): 108-9, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23347626
16.
ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
Crit Care Med
; 35(6): 1457-63, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17452935